Heligenics
Las Vegas, US · Founded 2019 · Nevada corporation
Biotech
Founders & leadership
MS
Martin SchillerExecutive Officer
LJ
Lawrence John LoomisChief Operating Office & Corporate Secretary
Reported raises · per SEC filings
Form D private placements▶$2.6MraisedJan 2025 · 8 investors · BiotechnologyRule 506(b)
▶$2.6MraisedJan 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin SchillerExecutive Officer
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- Minimum investment
- $10K
- First sale
- Aug 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.2MraisedAug 2022 · 12 investors · BiotechnologyRule 506(b)
▶$2.2MraisedAug 2022 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin R SchillerExecutive Officer
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Minimum investment
- $10K
- First sale
- Jun 2022
- Incorporated
- Corporation, Nevada, 2019
- Federal exemptions
- 06b
▶$1.2MraisedDec 2020 · 39 investors · BiotechnologyRule 506(b)
▶$1.2MraisedDec 2020 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence John LoomisExecutive Officer, Director
- Offering amount
- $2.4M
- Amount sold
- $1.2M
- Minimum investment
- $2K
- First sale
- Mar 2020
- Incorporated
- Corporation, Nevada, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $398.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.